KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Minority Interest (2016 - 2020)

Inovio Pharmaceuticals' Minority Interest history spans 11 years, with the latest figure at $96269.0 for Q3 2020.

  • For Q3 2020, Minority Interest fell 96.03% year-over-year to $96269.0; the TTM value through Sep 2020 reached $96269.0, down 96.03%, while the annual FY2019 figure was $2.0 million, 1946.1% up from the prior year.
  • Minority Interest for Q3 2020 was $96269.0 at Inovio Pharmaceuticals, roughly flat from $96269.0 in the prior quarter.
  • Across five years, Minority Interest topped out at $3.5 million in Q1 2020 and bottomed at $96269.0 in Q2 2016.
  • The 5-year median for Minority Interest is $96269.0 (2016), against an average of $807336.1.
  • The largest annual shift saw Minority Interest skyrocketed 3075.24% in 2019 before it tumbled 96.64% in 2020.
  • A 5-year view of Minority Interest shows it stood at $96269.0 in 2016, then changed by 0.0% to $96269.0 in 2017, then changed by 0.0% to $96269.0 in 2018, then skyrocketed by 1946.1% to $2.0 million in 2019, then plummeted by 95.11% to $96269.0 in 2020.
  • Per Business Quant, the three most recent readings for INO's Minority Interest are $96269.0 (Q3 2020), $96269.0 (Q2 2020), and $3.5 million (Q1 2020).